Inotiv Executive and Leadership Team

Robert Leasure, the Chief Executive Officer & President at Inotiv, directs the company's overarching strategy and operational execution. Leasure guides Inotiv's mission to support clients from early discovery through investigational new drug (IND) stages and beyond, ensuring a superlative client experience. This leadership involves aligning scientific capabilities with market demands, particularly in providing critical research models like rodents, rabbits, and nonhuman primates. Robert Leasure drives the company's growth by fostering a culture of attentive, decisive service, making every client program a priority. The focus remains on leveraging Inotiv's long regulatory history and world-class scientific team to deliver quality data on time, solidifying the company's position as a right-sized CRO.

Thomas Rao, the Principal Chief Executive Officer at Inotiv, spearheads the strategic direction and core operational philosophy of the organization. Rao's leadership emphasizes Inotiv's deep expertise and scientific capabilities, spanning the entire research continuum from initial discovery to post-IND support. This role involves ensuring that the company consistently delivers a superlative client experience, a commitment reinforced by its extensive history in supplying critical research models, including rodents, rabbits, and nonhuman primates. Thomas Rao champions the company's dedication to attentive, decisive service, positioning every program as a paramount priority. The emphasis is on maintaining an impeccable regulatory history and empowering a world-class team of scientists to guarantee on-time, quality data delivery.

John Beattie, the Chief Operating Officer at Inotiv, oversees the day-to-day operational execution and efficiency across the organization. Beattie ensures that Inotiv's deep expertise and scientific capabilities are seamlessly integrated to support clients throughout the discovery continuum, from initial research to investigational new drug (IND) applications and beyond. This involves optimizing the supply of critical research models, including rodents, rabbits, and nonhuman primates, to meet diverse client needs. John Beattie drives the company's commitment to attentive, decisive service, ensuring each program receives priority attention. The COO's focus is on maintaining operational excellence, upholding the company's long and impeccable regulatory history, and supporting the world-class team of scientists in delivering on-time, quality data.

Alison Bendele, the Founder and President of Bolder BioPATH at Inotiv, leads specialized scientific services and strategic development within the organization. Bendele's expertise drives Inotiv's capabilities in supporting clients from the beginning of discovery through investigational new drug (IND) applications and beyond, ensuring a superlative experience. This leadership focuses on leveraging deep scientific knowledge and a long history with critical research models, including rodents, rabbits, and nonhuman primates, to advance client projects. Alison Bendele cultivates a culture of attentive, decisive service, making every program a priority and ensuring the delivery of on-time, quality data. The role emphasizes innovation and scientific rigor, contributing significantly to Inotiv's position as a right-sized CRO.

Jeffrey Krupp, the Chief Human Resources Officer at Inotiv, directs all human capital strategies and organizational development initiatives. Krupp ensures that Inotiv cultivates a world-class team of scientists and support staff, fostering an environment that supports deep expertise and scientific capabilities across the discovery continuum. This leadership role is critical in attracting, retaining, and developing talent essential for delivering a superlative client experience from early discovery through investigational new drug (IND) stages. Jeffrey Krupp champions the company's culture of attentive, decisive service, ensuring that every employee understands their role in making client programs a priority. The focus is on building a robust workforce that upholds Inotiv's impeccable regulatory history and commitment to on-time, quality data delivery.